© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 91308 refers to a specific vaccine designed to provide immunity against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is responsible for the disease known as coronavirus disease (COVID-19). This vaccine utilizes a novel approach by employing messenger RNA (mRNA) technology encapsulated in lipid nanoparticles (LNP). The mRNA contained in the vaccine encodes the spike protein of the coronavirus, which is a critical component that the virus uses to enter human cells. Upon administration, the mRNA instructs the body's cells to produce copies of the spike protein, prompting the immune system to recognize it as a foreign entity. This recognition triggers an immune response, leading to the production of antibodies that can neutralize the virus if the individual is exposed in the future. The vaccine is specifically formulated for intramuscular use and is preservative-free, ensuring safety and efficacy for pediatric populations. It is important to note that this code is designated for the supply of the Pfizer two-dose pediatric vaccine, intended for children aged 6 months to 4 years, with doses administered at least 21 days apart. The preparation of the vaccine involves diluting it with preservative-free normal saline to achieve the correct dosage of 3 mcg per 0.2 mL, differing from the adult formulation, which includes additional buffering agents for stabilization. The actual administration of the vaccine is reported separately using the appropriate administration code, based on the dosage given.
© Copyright 2025 Coding Ahead. All rights reserved.
The CPT® Code 91308 is indicated for the vaccination against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), specifically for the prevention of coronavirus disease (COVID-19) in pediatric patients. The vaccine is intended for use in young children aged 6 months through 4 years, providing them with protection against the potentially severe and life-threatening effects of COVID-19.
The administration of the vaccine involves several key procedural steps to ensure proper delivery and efficacy. First, the vaccine must be prepared by diluting the concentrated vaccine formulation with preservative-free normal saline to achieve the appropriate dosage of 3 mcg per 0.2 mL. This step is crucial as it ensures that the vaccine is safe and effective for the pediatric population. Once the vaccine is prepared, the healthcare provider will select an appropriate site for intramuscular injection, typically in the thigh for young children. The injection site should be cleaned with an antiseptic to minimize the risk of infection. Following this, the healthcare provider will draw the diluted vaccine into a syringe, ensuring that no air bubbles are present. The vaccine is then administered intramuscularly, with the needle inserted at a 90-degree angle to the skin. After the injection, the provider may apply gentle pressure to the injection site with a cotton ball or gauze to prevent bleeding. It is important to monitor the patient for any immediate adverse reactions post-vaccination, and the administration of the vaccine is reported separately using the appropriate administration code, depending on the dose given.
After the administration of the vaccine, it is essential to monitor the patient for any immediate adverse reactions, which may include mild side effects such as soreness at the injection site, fever, or fatigue. These reactions are typically short-lived and resolve on their own. Parents or guardians should be informed about potential side effects and advised to seek medical attention if any severe reactions occur. Additionally, it is important to schedule the second dose of the vaccine at least 21 days after the first dose to ensure optimal immune response and protection against COVID-19. Documentation of the vaccination, including the date, dosage, and administration site, should be recorded in the patient's medical record for future reference and compliance with vaccination schedules.
| Short Descr | SARSCOV2 VAC 3 MCG TRS-SUCR | Medium Descr | SARSCOV2 VACCINE 3MCG/0.2ML TRIS-SUCROSE IM USE | Long Descr | Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use | Status Code | Not Valid for Medicare Purposes | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | APC Status Indicator | Non-Covered Service, not paid under OPPS | Berenson-Eggers TOS (BETOS) | none | MUE | Not applicable/unspecified. |
|
Date
|
Action
|
Notes
|
|---|---|---|
| 2025-01-01 | Deleted | First appearance of code deletion in codebook. |
| 2024-01-01 | Note | First appearance of 2022 CPT codebook guideline(s) changes in codebook. |
| 2023-11-01 | Deleted | Code deleted. See 91318, 91319, 91320, 91321, 91322. |
| 2023-04-18 | Note | Changes made to dosing information. |
| 2023-04-18 | Note | AMA guideline changed to include 0121A, 0151A, 0171A, & 0172A. Published to website 2023-05-01. Received FDA approval effective retroactively to 2023-04-18. |
| 2023-04-18 | Note | These codes (included in the guidelines) are no longer authorized for use in the United States: 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A. |
| 2023-04-18 | Note | No longer authorized for use in the United States. |
| 2023-03-14 | Note | AMA guideline changed to include 0174A. Published to website 2023-03-17. Received FDA approval effective retroactively to 2023-03-14. |
| 2023-01-01 | Added | First appearance in codebook. |
| 2022-12-08 | Note | CPT codebook guideline(s) changed to include 0173A. Published to website 2022-12-09. Received FDA approval effective retroactively to 2022-12-08. |
| 2022-10-12 | Note | CPT codebook guideline(s) changed. 0154A received FDA approval. |
| 2022-08-31 | Note | Changes made to vaccine name, product & dosing information, & patient age to (6 months through 4 years). |
| 2022-08-31 | Note | CPT codebook guideline(s) changed. 0124A received FDA approval effective immediately. |
| 2022-08-31 | Note | CPT codebook guideline(s) changed to include 0124A, 0154A effective upon receiving emergency Use Authorization or approval from the FDA. |
| 2022-06-17 | Added | FDA approval received |
| 2022-06-17 | Note | CPT codebook guideline(s) changed. 0081A, 0082A, 0083A, received FDA approval. |
| 2022-06-07 | Note | CPT codebook guideline(s) changed to include 0083A effective upon receiving Emergency Use Authorization or approval from the FDA. |
| 2022-05-17 | Note | CPT codebook guideline(s) changed. 0074A received FDA approval. |
| 2022-04-26 | Note | CPT codebook guideline(s) changed to include 0074A effective upon receiving Emergency Use Authorization or approval from the FDA. |
| 2022-02-01 | Added | Published on AMA website. Effective upon receiving emergency Use Authorization or approval from the FDA. |
| 2022-02-01 | Note | CPT codebook guideline(s) changed to include codes 0001A, 0002A, 0003A, 0004A, 0051A, 0052A, 0053A, 0054A, 0071A, 0072A, 0073A added to website & received FDA approval prior to the addition of 91308. |
| 2022-02-01 | Note | CPT codebook guideline(s) changed to include 0081A, 0082A effective upon receiving Emergency Use Authorization or approval from the FDA. |
Get instant expert-level medical coding assistance.